With the industry’s most highly characterized tumor bank of relevant clinical and molecular data, our models enable researchers to evaluate therapeutics alongside standards of care to facilitate therapeutic discovery with the goal of realizing predictive, efficacious results in patients.
Champions Oncology provides an end-to-end range of research and development solutions to deliver greater certainty in the fight against cancer. Our deep expertise includes screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic. Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.
Champions Oncology offers high-throughput drug screening, utilizing cell lines to evaluate tumor growth inhibition, investigating syngeneic models for the evaluation of immune-oncology agents, and ex vivo modeling with relevant endpoint analysis to more accurately and effectively gain predictive insight into clinical trial responses.
Champions Oncology’s translational research solutions comprise testing early throughout late stage therapeutics in humanized, hematology or solid tumor models, and our highly characterized and clinically-relevant cohorts of patient-derived xenograft (PDX) models to optimally predict success in drug development.
Champions Oncology offers a broad range of GCP-compliant validated flow cytometry panels, as well as the ability to develop custom validated assays, to deliver the in-depth understanding of targeted cell populations necessary to optimally support critical decision-making in all phases of drug development.
Champions Oncology has been attentively monitoring the impact of the novel Coronavirus (Covid-19) on our daily internal operations. Our priority is the well-being of our employees and the animals in our care, while also ensuring everyone stays healthy. Champions Oncology is working to manage the potential impact of the situation on our business and also ensure continuity to our customers externally. Our Executive Leadership Team is meeting frequently to evaluate the global circumstances and provide information and resources needed to manage the situation within our company as effectively as possible. Here are some actions that we are taking now to mitigate the effects on our business and in turn, to you our customers:
Operations:
Human Resources: